Valuation: Mabvax Therapeutics Holdings Inc

Market Cap 1.11M 971K 896K 823K 1.56M 107M 1.59M 10.69M 4.2M 52.23M 4.17M 4.08M 180M P/E 2016
-0.93x
P/E 2017 -0.25x
Enterprise Value 3.59M 3.14M 2.9M 2.66M 5.05M 346M 5.13M 34.58M 13.57M 169M 13.49M 13.19M 582M EV / Sales 2016
147x
EV / Sales 2017 -
Free-Float
92.02%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.88%-6.05%+6.42%+428.86% 23.87B
-0.13%-3.42%-18.36%-15.74% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.35%-0.45%+26.78%+191.09% 14.02B
Average +2.62%+0.34%+54.66%+202.36% 26.58B
Weighted average by Cap. +1.86%+0.47%+52.93%+157.54%

Financials

2016 2017
Net sales 148K 129K 119K 110K 208K 14.25M 212K 1.43M 559K 6.96M 556K 544K 24M -
Net income -17.66M -15.44M -14.24M -13.09M -24.81M -1.7B -25.23M -170M -66.72M -831M -66.32M -64.87M -2.86B -19.02M -16.63M -15.34M -14.1M -26.72M -1.83B -27.18M -183M -71.86M -895M -71.43M -69.86M -3.08B
Net Debt 470K 411K 379K 349K 660K 45.24M 672K 4.53M 1.78M 22.11M 1.77M 1.73M 76.21M 2.48M 2.17M 2M 1.84M 3.49M 239M 3.55M 23.89M 9.37M 117M 9.32M 9.11M 402M
Logo Mabvax Therapeutics Holdings Inc
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.
Employees
-